Compare Adaptive Biotechnologies Corp (ADPT) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Invesco S&P 500 Low Volatility ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.92 (market cap $4.04B), while Invesco S&P 500 Low Volatility ETF trades at $75.86. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Invesco S&P 500 Low Volatility ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | SPLV | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | — |
52-Week High | $25.45 | $77.97 |
52-Week Low | $12.30 | $70.30 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
SPLV trades at $75.78, showing minimal daily movement with a 0.11% gain. The ETF maintains a bullish technical signal with strong moving average support and oversold RSI conditions. Recent news highlights growing investor interest in low-volatility strategies amid market uncertainty, with SPLV positioned as a defensive option during periods of increased volatility and AI sector concerns.
The ETF's stability focus and consistent dividend payments provide defensive characteristics, though limited financial ratio data constrains fundamental analysis. Current technical positioning near key support levels suggests potential for stability, while market volatility concerns create favorable conditions for low-volatility strategies to outperform.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
